Standout Papers
Immediate Impact
1 by Nobel laureates 66 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Joseph Maly being referenced
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
2023
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Joseph Maly | 171 | 89 | 237 | 163 | 29 | 580 | |
| Atsushi Muto | 87 | 34 | 349 | 65 | 28 | 686 | |
| Dag Josefsen | 141 | 13 | 116 | 105 | 37 | 590 | |
| Christina Orsmark‐Pietras | 78 | 35 | 195 | 141 | 23 | 730 | |
| Solomon A. Graf | 164 | 137 | 62 | 94 | 44 | 678 | |
| Matthew M. Roforth | 156 | 35 | 86 | 56 | 27 | 713 | |
| Anıl Aktaş Samur | 262 | 25 | 249 | 48 | 35 | 544 | |
| Claire Hoyoux | 110 | 112 | 32 | 49 | 38 | 555 | |
| Eigo Shimizu | 109 | 71 | 73 | 125 | 32 | 539 | |
| Ritva Peltomaa | 44 | 52 | 120 | 32 | 27 | 552 | |
| Marianne Jacobsen | 110 | 59 | 63 | 56 | 20 | 596 |
All Works
Loading papers...